[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

1. Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases.Virchows Archiv : an international journal of pathology · 2009
   Article
2. Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer.Wiener klinische Wochenschrift · 2009
   Article
3. [NSCLC: update on second line therapy following ASCO 2007].Wiener medizinische Wochenschrift (1946) · 2007
   Review
4. ["Targeted Therapies" in NSCLC - present and future].Wiener medizinische Wochenschrift (1946) · 2007
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

20 authors at 11 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as